Avalo Therapeutics (NASDAQ: AVTX) net income
Avalo Therapeutics reported a net loss of $78.3m for fiscal 2025; in fiscal 2024 it reported a net loss of $35.1m. Earnings per share were −$5.84.
Avalo Therapeutics's best year of the last 10 was fiscal 2017. It reported a loss in 9 of those 10 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$78.3m | — | −132,642.4% | −$5.84 |
| 2024 | −$35.1m | — | −7,965.8% | −$7.94 |
| 2023 | −$31.5m | — | −1,639.5% | −$114.00 |
| 2022 | −$41.7m | — | −230.8% | −$4.43 |
| 2021 | −$84.4m | — | −1,563.1% | — |
| 2020 | −$63.5m | — | −947.9% | — |
| 2019 | −$16.1m | — | −238.1% | — |
| 2018 | −$40.1m | −437.4% | −569.9% | −$1.20 |
| 2017 | $11.9m | — | 42.7% | $0.42 |
| 2016 | −$16.5m | — | −1,428.6% | −$1.87 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Avalo Therapeutics net income compared with its sector
By net income for its latest fiscal year, Avalo Therapeutics ranks 309th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Avalo Therapeutics, −132,642.4%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 307th | Twist Bioscience | −$77.7m | −20.6% |
| 308th | Surgery Partners | −$77.9m | −2.4% |
| 309th | Avalo Therapeutics | −$78.3m | −132,642.4% |
| 310th | Corbus Pharmaceuticals | −$78.5m | — |
| 311th | X4 Pharmaceuticals | −$79.2m | −225.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Avalo Therapeutics
- How much did Avalo Therapeutics earn in fiscal 2025?
- Avalo Therapeutics reported a net loss of $78.3m for fiscal 2025. In fiscal 2024 it reported a net loss of $35.1m.
- What are the earnings per share of Avalo Therapeutics?
- They were −$5.84 in fiscal 2025, compared with −$7.94 in fiscal 2024.
- What was the most profitable year for Avalo Therapeutics?
- Of its last 10 fiscal years, fiscal 2017, with $11.9m.
- Where does Avalo Therapeutics rank in its sector by net income?
- It ranks 309th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Avalo Therapeutics come from?
- From the annual report (Form 10-K) that Avalo Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Avalo Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Avalo Therapeutics: the Avalo Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.